Zheng Wei

CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice.

T. Schall, I. Charo, T. Sullivan, 2013, American journal of physiology. Renal physiology.

CCR 2 antagonist CCX 140-B provides renal and glycemic benefits in diabetic transgenic human CCR 2 knockin mice

T. Schall, I. Charo, T. Sullivan, 2013 .

Characterization of CCX140-B, an orally bioavailable antagonist of the CCR2 chemokine receptor, for the treatment of type 2 diabetes and associated complications.

T. Schall, I. Charo, Daniel M. Johnson, 2012, The Journal of pharmacology and experimental therapeutics.

Proinflammatory Proteases Liberate a Discrete High-Affinity Functional FPRL1 (CCR12) Ligand from CCL2312

B. Premack, T. Schall, M. Howard, 2007, The Journal of Immunology.

Characterization of CCX282-B, an Orally Bioavailable Antagonist of the CCR9 Chemokine Receptor, for Treatment of Inflammatory Bowel Disease

Yu Wang, T. Schall, J. Jaén, 2010, Journal of Pharmacology and Experimental Therapeutics.

Cc chemokine receptor 9 (ccr9) antagonist ameliorates experimental ileitis and colitis

T. Schall, W. Rubas, M. Howard, 2005 .

Evidence for NK Cell Subsets Based on Chemokine Receptor Expression1

L. Lanier, T. Schall, R. Berahovich, 2006, The Journal of Immunology.